Long-Term Outcomes of Sotorasib Efficacy in Patients With KRASG12C Mutated NSCLC

Opinion
Video

CodeBreaK 100 compares the safety and efficacy of pembrolizumab combined with adagrasib or sotorasib in treating KRAS G12C NSCLC, noting sotorasib has a longer presence and familiarity in clinical use.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Stage IV lung cancer may be curable based on the success of the DREAM Program, according to thoracic surgeon, Ankit Bharat, MBBS,
Ankit Bharat, MBBS, a thoracic surgeon, discussed potential treatment emergent adverse effects or complications, as well as strategies for managing them.
Thoracic surgeon, Ankit Bharat, MBBS, discussed surgical strategies among patients with advanced lung cancer diagnoses based on staging.
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Treatment with lorlatinib might be effective regardless of the presence of central nervous system metastases, according to Misako Nagasaka, MD, PhD.
Most central nervous system events with lorlatinib were grade 1 or 2 in the phase 3 CROWN trial.
Treatment with lorlatinib did not increase cardiovascular events among patients with ALK-positive non–small cell lung cancer in the CROWN trial.
Related Content
Following the induction phase with chemotherapy alone, ibrilatazar has shown a manageable toxicity profile in patients with advanced squamous NSCLC.

Ibrilatazar Shows Survival Improvement in Advanced Squamous NSCLC

Roman Fabbricatore
June 6th 2025
Article

Following the induction phase with chemotherapy alone, ibrilatazar has shown a manageable toxicity profile in patients with advanced squamous NSCLC.

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

Improving NSCLC Surgery Recovery After Climate Disaster Exposure

Leticia Nogueira, PhD, MPH
March 31st 2025
Podcast

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

The DREAM program led by Ankit Bharat, MD, MBBS, FACS, allowed Cornelia Tischmacher to receive a double lung transplant for her stage IV lung cancer.

An International Search for Lung Cancer Treatment Leads to Double Lung Transplant

Roman Fabbricatore
June 4th 2025
Article

The DREAM program led by Ankit Bharat, MD, MBBS, FACS, allowed Cornelia Tischmacher to receive a double lung transplant for her stage IV lung cancer.

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Navigating Management and Dosing Considerations for Amivantamab in NSCLC

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
February 10th 2025
Podcast

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Significant OS Benefit Observed With NAT Nivolumab/Chemo in Resectable NSCLC

Significant OS Benefit Observed With NAT Nivolumab/Chemo in Resectable NSCLC

Kristi Rosa
June 3rd 2025
Article

Results from CheckMate-816 could be practice-changing after an OS improvement was noted with NAT nivolumab plus chemotherapy in resectable NSCLC.

Efficacy and biomarker analyses from CheckMate-77T support perioperative nivolumab as an effective option in resectable NSCLC.

Nivolumab Extends EFS Across Resectable NSCLC Subgroups

Caroline Seymour
June 3rd 2025
Article

Efficacy and biomarker analyses from CheckMate-77T support perioperative nivolumab as an effective option in resectable NSCLC.